# Semax – 10mg/vial (Research Use Only)

### Overview

Semax is a synthetic nootropic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the ACTH(4-10) core fragment extended with a Pro-Gly-Pro C-terminal tripeptide for improved metabolic stability. Originally studied for cerebrovascular and neuroprotective applications, Semax has generated a published research base spanning BDNF upregulation, dopaminergic and serotonergic system modulation, ischemia-reperfusion research, and cognitive function biomarker studies in rodent models. It holds regulatory approval in Russia and Ukraine as a nootropic peptide drug.

### What It Is

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, MW approximately 779 Da, CAS number 80714-61-0. It is a structural analogue of ACTH(4-7) (Met-Glu-His-Phe) with the C-terminal Pro-Gly-Pro extension borrowed from the Selank research program to confer enzymatic stability. Semax does not bind melanocortin receptors at pharmacologically relevant concentrations but has been shown in published research to upregulate BDNF and NGF expression, modulate dopamine system markers, and affect serotonin transporter activity.

### Key Research Applications

- BDNF and NGF upregulation in cortical and hippocampal tissue research
- Cerebrovascular research — ischemia-reperfusion injury and neuroprotection modeling
- Dopaminergic system modulation and D1/D2 receptor expression studies
- Serotonin transporter (SERT) and serotonergic signaling research
- Cognitive function biomarker and memory consolidation studies in rodent models
- ACTH fragment pharmacology without adrenocortical activation
- Nootropic peptide comparative pharmacology vs. Selank and other ACTH-derived peptides
- Stroke, traumatic brain injury, and hypoxia preclinical modeling studies

### Technical Specifications

| Amino Acids | 7 (Met-Glu-His-Phe-Pro-Gly-Pro) |
| --- | --- |
| Molecular Weight | ~779 Da |
| CAS Number | 80714-61-0 |
| Parent Structure | ACTH(4-7) + Pro-Gly-Pro extension |
| Purity | ≥98% (supplier specification) |
| Form | Lyophilized powder |
| Vial Size | 10mg |
| Storage | −4 °F long-term |

**FOR RESEARCH USE ONLY.** Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

Regulatory Status Note

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was **not** recommended. FDA’s own briefing documents had recommended against all seven.

A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. [Source: FDA Advisory Committee Calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) . Last reviewed: August 17, 2026.

---

Source: https://portaltowellness.net/shop/semax-10mg-vial/
Research use only. Terms: https://portaltowellness.net/research-use-only/